An international consortium was initiated with the support of the Society for Immunotherapy of Cancer to assess the prognostic value of total tumor-infiltrating T cell counts and cytotoxic tumor-infiltrating T cell counts with the consensus immunoscore assay in patients with stages I–III colon cancer, and the densities of CD3+ and cytotoxic CD8+ T cells in the tumor and the invasive margin were quantified by digital pathology (24). The gene discussed is CD8A; the disease is neoplasm.